← Leaderboards
John D Gordan
University Of California, San Francisco
$2,714,177
Attributed
$3,361,296
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,361,296 · 2
By mechanism
R37$2,067,058 · 1
R01$1,294,238 · 1
Top collaborators
- John D Scott4 shared
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Bruce Mao Zheng Wang$2,850,462
Others in their field
Other Rising Stars on “Phosphotransferases”
- Julian A Symons · Hackensack University Medical Center$4,228,031
- Fouad T Chebib · Mayo Clinic Jacksonville$2,967,657
- Chao Peng · University Of California Los Angeles$2,714,628
- Mark Yarchoan · Johns Hopkins University$2,710,792
- Nagendran Ramalingam · Brigham And Women'S Hospital$2,504,321
- Irida Kastrati · Loyola University Chicago$2,252,222
Research focus
PhosphotransferasesTargeted TreatmentMalignant NeoplasmsPharmaceutical PreparationsSignal TransductionResponseGenetic TranscriptionLinkOncogenicPatient Derived Xenograft ModelRegimenProteomicsRegulationResistanceCellsDependenceInhibitorIn VivoMutantMutationOutputPathway InteractionsCell LineToxic Effect
Grant awards (8)
Targeting Oncogenic PKA signaling mechanisms$588,909
R01 · FY2025 · CA · contact PI
Understanding intrinsic resistance to direct KRAS inhibition in colorectal cancers$526,540
R37 · FY2025 · CA · contact PI
Targeting Oncogenic PKA signaling mechanisms$67,817
R01 · FY2025 · CA · contact PI
Targeting Oncogenic PKA signaling mechanisms$616,676
R01 · FY2024 · CA · contact PI
Understanding intrinsic resistance to direct KRAS inhibition in colorectal cancers$498,202
R37 · FY2024 · CA · contact PI
Characterizing the biochemical mechanisms of oncogenic signaling by mutant Protein Kinase A$20,836
R01 · FY2024 · CA · contact PI
Understanding intrinsic resistance to direct KRAS inhibition in colorectal cancers$515,894
R37 · FY2023 · CA · contact PI
Understanding intrinsic resistance to direct KRAS inhibition in colorectal cancers$526,422
R37 · FY2022 · CA · contact PI